Thus, in vitro studies in several models of lysosomal impairment, including ATP13A2-mutant cells, GBA-mutant fibroblasts from PD patients, and neuroblastoma cells treated with lysosomotropic agents pathologically enhancing lysosomal pH, demonstrate that PLGA acidic nanoparticles can enhance cell survival and restore the physiological pH of the lysosome lumen [177]. This evidence concerns the gene GBA1 and Parkinson disease.